Gurnet Point Capital

Alladapt Immunotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for food allergies. Founded in 2018 and based in Menlo Park, California, the company is advancing its lead program, ADP101, which aims to provide a broad-spectrum oral immunotherapy treatment. This innovative drug targets the mitigation, treatment, and prevention of food allergies caused by single or multiple proteins from a wide range of common allergens. Through its research and development efforts, Alladapt Immunotherapeutics seeks to enable healthcare providers to effectively address the challenges faced by patients with various food allergies.

Developer of artificial intelligence-powered in-vitro fertilization decision support system. intended to provide an accurate embryo classification and implantation prediction. The company's platform offers services that use computer vision algorithms and big data to significantly increase the efficiency of IVF and reduce the time to live birth, enabling patients with proper and early data-driven embryo quality assessment leading to improved pregnancy rates with shorter and fewer IVF cycles.

Mahana Therapeutics, Inc. develops an application for treating patients suffering from gastrointestinal (GI) diseases and conditions. The company offers Parallel, a clinically-validated and minimal-contact digital program for people with irritable bowel syndrome (IBS). Mahana Therapeutics, Inc. was formerly known as Mahana Health, Inc. and changed its name to Mahana Therapeutics, Inc. in July 2019. The company was incorporated in 2018 and is based in San Francisco, California. It has an additional location in London, United Kingdom.

Naveris Inc. is a biotechnology company specializing in the development of sensitive blood tests for early cancer detection, which enhances patient outcomes. Founded in 2017 and based in Waltham, Massachusetts, Naveris offers NavDx, a blood test that identifies human papilloma virus-associated cancers by quantifying tumor-specific DNA fragments released into the bloodstream. The company's innovative biomimetic technology simulates the complexities of human tissues and tumors, facilitating early diagnosis in asymptomatic individuals, real-time monitoring of treatment responses, and the detection of cancer recurrence in patients in remission. Naveris aims to improve oncology clinical trials and precision medicine, ensuring that therapies are effectively matched to individual patients.

Zikani Therapeutics, Inc. develops and commercializes therapeutics for patients with limited treatment options. It offers TURBO-ZM, a platform to develop novel ribosome modulating agents (RMAs) for the treatment of cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Zikani Therapeutics, Inc. was formerly known as Macrolide Pharmaceuticals, Inc. and changed its name to Zikani Therapeutics, Inc. in February 2015. Zikani Therapeutics, Inc. was incorporated in 2014 and is based in Watertown, Massachusetts.

Alladapt Immunotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for food allergies. Founded in 2018 and based in Menlo Park, California, the company is advancing its lead program, ADP101, which aims to provide a broad-spectrum oral immunotherapy treatment. This innovative drug targets the mitigation, treatment, and prevention of food allergies caused by single or multiple proteins from a wide range of common allergens. Through its research and development efforts, Alladapt Immunotherapeutics seeks to enable healthcare providers to effectively address the challenges faced by patients with various food allergies.

Axcella Health Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, specializing in the research and development of endogenous metabolic modulators (EMMs) to address complex diseases and enhance overall health. The company focuses on amino acid homeostasis and has identified over 2,000 diseases linked to amino acid imbalances. Axcella has developed a systems pharmacology approach to restore health at the cellular level, leading to a range of clinical-stage candidates targeting conditions such as hepatic encephalopathy, non-alcoholic steatohepatitis, muscle atrophy, and various biological pathways related to blood health. Founded in 2008 and previously known as Newco LS16, Inc., Axcella aims to pioneer innovative treatments that have the potential to significantly impact the therapeutic landscape.

Corium International, Inc. is a biopharmaceutical company specializing in the development, manufacture, and commercialization of specialty pharmaceutical products that utilize transdermal and transmucosal delivery systems. The company offers several products, including a clonidine transdermal delivery system for hypertension, fentanyl patches for chronic pain management, and Crest Whitestrips for teeth whitening. Its product pipeline features innovative therapies, such as Twirla, a hormonal contraceptive patch, and a transdermal system for severe osteoporosis. Additionally, Corium is developing transdermal systems for Alzheimer's disease, psychiatric disorders, and motion sickness. The company collaborates with various pharmaceutical partners to advance its product offerings. Established in 1995, Corium International is headquartered in Menlo Park, California, and operates with a focus on enhancing therapeutic outcomes through advanced drug delivery technologies.

Zikani Therapeutics, Inc. develops and commercializes therapeutics for patients with limited treatment options. It offers TURBO-ZM, a platform to develop novel ribosome modulating agents (RMAs) for the treatment of cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Zikani Therapeutics, Inc. was formerly known as Macrolide Pharmaceuticals, Inc. and changed its name to Zikani Therapeutics, Inc. in February 2015. Zikani Therapeutics, Inc. was incorporated in 2014 and is based in Watertown, Massachusetts.

Innocoll is a privately held international biopharmaceutical company based in Athlone, Ireland, specializing in collagen-based pharmaceutical products and medical devices. The company develops biodegradable and fully bioresorbable products aimed at addressing patient needs, particularly in postsurgical pain management and infection prevention. Its key offerings include CollaGUARD, a bioresorbable collagen film designed to prevent post-operative adhesions; Collatamp Gentamicin, a surgical implant for infection treatment; and Septocoll, a dual-action collagen sponge for infection prevention. Innocoll also produces RegenePro, a collagen sponge for dental applications. The company's product candidates include XaraColl, an implantable collagen matrix in phase III trials for pain relief, and Cogenzia, a topical collagen sponge for diabetic foot infections. Through its proprietary technology platform, Innocoll focuses on delivering non-opioid pain management alternatives for various surgical procedures.

BEFORE Brands, Inc. is a science-based consumer products company founded in 2015 and located in Menlo Park, California. The company specializes in developing nutritional products aimed at supporting the health and wellness of families, particularly infants. Its innovative offerings leverage a proprietary formulation known as Early Adaptive Tolerance, which combines whole food proteins and vitamin D to provide balanced and gentle immune system support from an early age. This approach is rooted in research led by Dr. Kari Nadeau, a pediatrician and director at the Sean N. Parker Center for Allergy and Asthma Research at Stanford University. BEFORE Brands emphasizes the importance of incorporating potentially allergenic foods into a healthy diet, aiming to train the immune system effectively and prevent future health issues.

Crossover Health, Inc. is a healthcare provider focused on delivering comprehensive workplace healthcare services tailored for employers and their employees. Founded in 2010 and headquartered in Aliso Viejo, California, the company operates health centers in various locations, including Silicon Valley. Crossover Health offers a wide range of services, such as primary care, urgent care, preventive care, chronic disease management, health education, physical therapy, and remote care, among others. By integrating various health and wellness benefits with technology-enabled services, Crossover Health aims to enhance access to care and reduce healthcare costs for companies. The firm collaborates closely with client partners to customize health services based on health analytics, fostering a culture of health ownership among employees while improving both the quality of care and the overall employee experience.

Auregen BioTherapeutics is a biotechnology company focused on developing innovative treatments for rare disorders, particularly congenital craniofacial conditions. The company specializes in 3D bioprinting technology and rare disease cell therapy, aiming to create effective solutions for patients with these challenging medical issues. By leveraging advanced bioprinting techniques, Auregen seeks to explore new treatment options that could significantly improve the quality of life for individuals affected by rare diseases.

Amazentis SA is a life science company based in Lausanne, Switzerland, founded in 2007. The company specializes in the research and development of bioactive ingredients aimed at advanced therapeutic nutrition, particularly for the aging population. Amazentis focuses on creating products that enhance mitochondrial health, addressing age-related muscle decline by improving mitochondrial activity. Utilizing proprietary technology, the company mimics the effects of certain foods, like pomegranates, to repair damage in mitochondria and promote an active lifestyle. Through its innovative approach, Amazentis aims to meet specific health needs, particularly in hospital settings, by optimizing muscle function and overall well-being.

Axcella Health Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, specializing in the research and development of endogenous metabolic modulators (EMMs) to address complex diseases and enhance overall health. The company focuses on amino acid homeostasis and has identified over 2,000 diseases linked to amino acid imbalances. Axcella has developed a systems pharmacology approach to restore health at the cellular level, leading to a range of clinical-stage candidates targeting conditions such as hepatic encephalopathy, non-alcoholic steatohepatitis, muscle atrophy, and various biological pathways related to blood health. Founded in 2008 and previously known as Newco LS16, Inc., Axcella aims to pioneer innovative treatments that have the potential to significantly impact the therapeutic landscape.

Zikani Therapeutics, Inc. develops and commercializes therapeutics for patients with limited treatment options. It offers TURBO-ZM, a platform to develop novel ribosome modulating agents (RMAs) for the treatment of cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Zikani Therapeutics, Inc. was formerly known as Macrolide Pharmaceuticals, Inc. and changed its name to Zikani Therapeutics, Inc. in February 2015. Zikani Therapeutics, Inc. was incorporated in 2014 and is based in Watertown, Massachusetts.